Studies suggest that the STING agonist cGAMP not only directly enhances NK cell‐mediated anti‐tumor activity but also increases the sensitivity of pancreatic cancer cells to NK cell cytotoxicity, thereby exerting anti‐tumor effects in this context (Da et al. 2022). Here, STING1 is linked to familial pancreatic carcinoma.